Dihydroxyacetone, pyruvate, and phosphate effects on 2,3 DPG and ATP in citrate-phosphate-dextrose-adenine blood preservation.
Blood was stored with various combinations of 60 mM dihydroxyacetone (DHA), 80 mM pyruvate and 10 mM phosphate in citrate-phosphate-dextrose-adenine-one (CPDA-1) preservative for 42 days. During that time, DHA was found to have a beneficial effect on 2,3 diphosphoglycerate (2,3 DPG), although a deleterious effect on adenosine triphosphate (ATP). Preservatives containing pyruvate gave similar results. However, DHA and phosphate together in CPDA-1 improved both 2,3 DPG and ATP. The adverse effect on 2,3 DPG levels that phosphate normally shows was reversed by the addition of DHA. These results indicate that the addition of phosphate alone, rather than pyruvate, or pyruvate and phosphate, to DHA in CPDA-1 would be preferable to the presently licensed CPDA-1 preservative.
D019794:2,3-Diphosphoglycerate; D000225:Adenine / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000097:blood*; D001793:Blood Preservation; D002951:Citrates / Q000494:pharmacology*; D004098:Dihydroxyacetone / Q000494:pharmacology*; D004163:Diphosphoglyceric Acids / Q000097:blood*; D004905:Erythrocyte Aging / Q000187:drug effects; D004912:Erythrocytes / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D010710:Phosphates / Q000494:pharmacology*; D011773:Pyruvates / Q000494:pharmacology; D019289:Pyruvic Acid; D014306:Trioses / Q000494:pharmacology*
C034876:CPDA solutions; D002951:Citrates; D004163:Diphosphoglyceric Acids; D010710:Phosphates; D011773:Pyruvates; D014306:Trioses; D019794:2,3-Diphosphoglycerate; D019289:Pyruvic Acid; D000255:Adenosine Triphosphate; D005947:Glucose; D000225:Adenine; D004098:Dihydroxyacetone